Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC

Author(s):

Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer CenterChristine Bestvina, MD, University of Chicago

This episode explores expert insights on the clinical use of osimertinib in the frontline setting for EGFR-mutated NSCLC, the impact of combining osimertinib with platinum-based chemotherapy on progression-free survival (PFS), and the significance of extending PFS by nearly 9 months in patients with advanced NSCLC who are not candidates for curative treatment.

Now Viewing

EP: 1.Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC

Video content above is prompted by the following:

What has been your clinical experience with osimertinib in the frontline setting for EGFR-mutated NSCLC?

Please assess the impact of a 38% improvement in PFS with the combination of osimertinib and platinum-based chemotherapy vs osimertinib monotherapy in patients with advanced EGFR-mutated NSCLC.

From the perspective of a community oncologist, please share your insights on the meaningful benefit of extending PFS an additional 8.8-9.5 months among untreated patients with advanced NSCLC, not amenable to curative resection or radiotherapy.